Brian Pereira
Chief Executive Officer chez VISTERRA INC
Fortune : 2 M $ au 31/03/2024
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
T. Crockett | M | 49 |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | 20 ans |
Michael Amoroso | M | 46 | 4 ans | |
Ben Palleiko | M | 58 | 8 ans | |
Nikhil Pereira-Kamath | M | - |
Africa Healthcare Network Rwanda Ltd.
Africa Healthcare Network Rwanda Ltd. Medical/Nursing ServicesHealth Services Africa Healthcare Network Rwanda Ltd. operates kidney dialysis centers and hospitals. The company was founded by Nikhil Pereira-Kamath, Brian J.G. Pereira and Lloyd Vincent in 2015 and is headquartered in Kigali, South Africa. | 9 ans |
Lata Krishnan | F | 62 |
American India Foundation
| 23 ans |
Albert Cha | M | 51 |
Biodel, Inc.
Biodel, Inc. Pharmaceuticals: MajorHealth Technology Biodel, Inc. is a pharmaceutical company, which develops novel formulations of already approved therapeutics to treat endocrine disorders such as diabetes and osteoporosis. The company develops product candidates by applying formulation technologies to existing drugs in order to improve their therapeutic profiles. Biodel was founded by Solomon S. Steiner and Erik Steiner on December 3, 2003 and is headquartered in Danbury, CT.
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | 11 ans |
Ed Feener | M | 64 |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | 20 ans |
Tim Bertram | M | 68 |
ProKidney LLC
ProKidney LLC Packaged SoftwareTechnology Services ProKidney LLC develops therapies for kidney disease. The company was founded by Pablo Legorreta and is headquartered in Winston-Salem, NC. | 5 ans |
Chris Kiefer | M | - | 7 ans | |
Bruce Culleton | M | 57 | 1 ans | |
Lloyd Vincent | M | - |
Africa Healthcare Network Rwanda Ltd.
Africa Healthcare Network Rwanda Ltd. Medical/Nursing ServicesHealth Services Africa Healthcare Network Rwanda Ltd. operates kidney dialysis centers and hospitals. The company was founded by Nikhil Pereira-Kamath, Brian J.G. Pereira and Lloyd Vincent in 2015 and is headquartered in Kigali, South Africa. | - |
Edward Unkart | M | 74 |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | 10 ans |
Stephen Gerard Donnelly | M | - |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | - |
Uma Sinha | M | 67 | - | |
Deepak Jain | M | 70 |
ProKidney LLC
ProKidney LLC Packaged SoftwareTechnology Services ProKidney LLC develops therapies for kidney disease. The company was founded by Pablo Legorreta and is headquartered in Winston-Salem, NC. | 8 ans |
Rachel Morten | F | - | 8 ans | |
James Coulston | M | 48 |
ProKidney LLC
ProKidney LLC Packaged SoftwareTechnology Services ProKidney LLC develops therapies for kidney disease. The company was founded by Pablo Legorreta and is headquartered in Winston-Salem, NC. | 5 ans |
Jennifer Fox | F | 53 | 2 ans | |
Pablo Legorreta | M | 60 |
ProKidney LLC
ProKidney LLC Packaged SoftwareTechnology Services ProKidney LLC develops therapies for kidney disease. The company was founded by Pablo Legorreta and is headquartered in Winston-Salem, NC. | 2 ans |
Christopher Yea | M | 61 |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | 9 ans |
Todd Curtis | M | - | 9 ans | |
Robert Haigh | M | 64 |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | 13 ans |
Greg Gin | M | - | 4 ans | |
Todd Girolamo | M | 59 | 2 ans | |
John Maraganore | M | 60 | 2 ans | |
Richard H. Aldrich | M | 69 |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | 4 ans |
Nancy Stuart | F | 65 | 3 ans | |
Victor J. Menezes | M | - |
American India Foundation
| - |
Satjiv Chahil | M | 72 |
American India Foundation
| - |
José Ignacio Jiménez Santos | M | 49 | - | |
Matt Williams | M | - |
Africa Healthcare Network Rwanda Ltd.
Africa Healthcare Network Rwanda Ltd. Medical/Nursing ServicesHealth Services Africa Healthcare Network Rwanda Ltd. operates kidney dialysis centers and hospitals. The company was founded by Nikhil Pereira-Kamath, Brian J.G. Pereira and Lloyd Vincent in 2015 and is headquartered in Kigali, South Africa. | 2 ans |
Libbie McKenzie | M | 51 |
ProKidney LLC
ProKidney LLC Packaged SoftwareTechnology Services ProKidney LLC develops therapies for kidney disease. The company was founded by Pablo Legorreta and is headquartered in Winston-Salem, NC. | 2 ans |
Patrick Treanor | M | - | 2 ans | |
Ajaypal Banga | M | 65 |
American India Foundation
| 8 ans |
Bill Doyle | M | 61 | 2 ans | |
Alan Lotvin | M | 62 | 2 ans | |
Joseph Stavas | M | 69 | 5 ans | |
Sunita Pereira | F | - |
American India Foundation
| - |
Toshiki Sudo | M | - | - | |
Harren Jhoti | M | - | - | |
Burns McClellan | M | - | - | |
Greg Babcock | M | - | 11 ans | |
Nita Gangwal | F | - |
American India Foundation
| - |
Bulbul Bahuguna | F | - |
American India Foundation
| - |
Ritu Chugh | F | - |
American India Foundation
| - |
Jarrod Aldom | M | - | - | |
Tania Mirchandani | F | - |
American India Foundation
| - |
Dinesh Mirchandani | M | - |
American India Foundation
| - |
Usha Nesamoney | F | - |
American India Foundation
| - |
Aparna Ramaswamy | F | - |
American India Foundation
| 3 ans |
Nancy Patel | F | - |
American India Foundation
| - |
Arjun Sanyal | M | - |
American India Foundation
| - |
Ravi Tilak | M | - |
American India Foundation
| - |
Lloyd Paul Aiello | M | - |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | 13 ans |
Raj Seshadri | F | 58 |
American India Foundation
| 5 ans |
Sanjay Sinho | M | - |
American India Foundation
| - |
Dinesh C. Paliwal | M | 67 |
American India Foundation
| 12 ans |
Harit Talwar | M | 63 |
American India Foundation
| - |
Kumar Malavalli | M | - |
American India Foundation
| - |
Arnold Lewis Oronsky | M | 83 |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | - |
Ravindranath Akhoury | M | 77 |
American India Foundation
| - |
Robert McQuade | M | 67 | - | |
Rohit Kapoor | M | 59 |
American India Foundation
| 6 ans |
Sumir Chadha | M | 53 |
American India Foundation
| - |
Vivek Chopra | M | - |
American India Foundation
| - |
Pradeep Kashyap | M | - |
American India Foundation
| - |
Shigeru Handa | M | - |
Africa Healthcare Network Rwanda Ltd.
Africa Healthcare Network Rwanda Ltd. Medical/Nursing ServicesHealth Services Africa Healthcare Network Rwanda Ltd. operates kidney dialysis centers and hospitals. The company was founded by Nikhil Pereira-Kamath, Brian J.G. Pereira and Lloyd Vincent in 2015 and is headquartered in Kigali, South Africa. | - |
Adil Siraj Zainulbhai | M | 70 |
American India Foundation
| - |
Manu Anand | M | 64 |
American India Foundation
| - |
Saurabh Srivastava | M | 78 |
American India Foundation
| - |
Ajay Shah | M | 64 |
American India Foundation
| - |
Darin Weber | M | 56 | 4 ans | |
Raj Bhatia | M | - |
American India Foundation
| - |
Neil Herson | M | - |
Africa Healthcare Network Rwanda Ltd.
Africa Healthcare Network Rwanda Ltd. Medical/Nursing ServicesHealth Services Africa Healthcare Network Rwanda Ltd. operates kidney dialysis centers and hospitals. The company was founded by Nikhil Pereira-Kamath, Brian J.G. Pereira and Lloyd Vincent in 2015 and is headquartered in Kigali, South Africa. | - |
Derek Chen Brand | M | - |
Africa Healthcare Network Rwanda Ltd.
Africa Healthcare Network Rwanda Ltd. Medical/Nursing ServicesHealth Services Africa Healthcare Network Rwanda Ltd. operates kidney dialysis centers and hospitals. The company was founded by Nikhil Pereira-Kamath, Brian J.G. Pereira and Lloyd Vincent in 2015 and is headquartered in Kigali, South Africa. | - |
Kelechi Ohiri | M | - |
Africa Healthcare Network Rwanda Ltd.
Africa Healthcare Network Rwanda Ltd. Medical/Nursing ServicesHealth Services Africa Healthcare Network Rwanda Ltd. operates kidney dialysis centers and hospitals. The company was founded by Nikhil Pereira-Kamath, Brian J.G. Pereira and Lloyd Vincent in 2015 and is headquartered in Kigali, South Africa. | - |
Jean Bender | F | - | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Frank Thomas | M | 54 | 6 ans | |
Jerome Goldstein | M | 84 | 26 ans | |
David Arkowitz | M | 62 | 10 ans | |
Solomon Steiner | M | 86 |
Biodel, Inc.
Biodel, Inc. Pharmaceuticals: MajorHealth Technology Biodel, Inc. is a pharmaceutical company, which develops novel formulations of already approved therapeutics to treat endocrine disorders such as diabetes and osteoporosis. The company develops product candidates by applying formulation technologies to existing drugs in order to improve their therapeutic profiles. Biodel was founded by Solomon S. Steiner and Erik Steiner on December 3, 2003 and is headquartered in Danbury, CT. | 8 ans |
Scott A. Holmes | M | 50 | 4 ans | |
Davey Scoon | M | 78 |
Biodel, Inc.
Biodel, Inc. Pharmaceuticals: MajorHealth Technology Biodel, Inc. is a pharmaceutical company, which develops novel formulations of already approved therapeutics to treat endocrine disorders such as diabetes and osteoporosis. The company develops product candidates by applying formulation technologies to existing drugs in order to improve their therapeutic profiles. Biodel was founded by Solomon S. Steiner and Erik Steiner on December 3, 2003 and is headquartered in Danbury, CT. | 14 ans |
Mark Stejbach | M | 61 | 4 ans | |
Michael Narachi | M | 64 | 8 ans | |
Joao Siffert | M | 60 | 2 ans | |
Joseph Farmer | M | 52 | - | |
Gerard Michel | M | 60 |
Biodel, Inc.
Biodel, Inc. Pharmaceuticals: MajorHealth Technology Biodel, Inc. is a pharmaceutical company, which develops novel formulations of already approved therapeutics to treat endocrine disorders such as diabetes and osteoporosis. The company develops product candidates by applying formulation technologies to existing drugs in order to improve their therapeutic profiles. Biodel was founded by Solomon S. Steiner and Erik Steiner on December 3, 2003 and is headquartered in Danbury, CT. | 7 ans |
Errol de Souza | M | 70 |
Biodel, Inc.
Biodel, Inc. Pharmaceuticals: MajorHealth Technology Biodel, Inc. is a pharmaceutical company, which develops novel formulations of already approved therapeutics to treat endocrine disorders such as diabetes and osteoporosis. The company develops product candidates by applying formulation technologies to existing drugs in order to improve their therapeutic profiles. Biodel was founded by Solomon S. Steiner and Erik Steiner on December 3, 2003 and is headquartered in Danbury, CT. | 6 ans |
Stephen B. Howell | M | 79 | 24 ans | |
Timothy G. Healey | M | 58 | - | |
Ron Zwanziger | M | 70 | 5 ans | |
Mark Alvino | M | 56 | 14 ans | |
Joseph Vincent Bonventre | M | 74 | 5 ans | |
Will Price | M | - |
Kellogg School of Management
| 2 ans |
Stefano Buono | M | 57 | 2 ans | |
Shane McCarthy | M | - |
Kellogg School of Management
| 3 ans |
Paul Mann | M | 48 | - | |
Parvinder S. Hyare | M | - | - | |
Richard van Dyune | M | 70 | 2 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 90 | 90,00% |
Royaume-Uni | 10 | 10,00% |
Afrique du Sud | 7 | 7,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Brian Pereira
- Réseau Personnel